<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>作为您在 Google 上的首选新闻来源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>强生（Johnson &amp; Johnson，JNJ）宣布，美国食品和药物管理局（FDA）已批准 RYBREVANT FASPRO（阿米万单抗和透明质酸酶-lpuj），这是首个也是唯一一个用于治疗表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC）患者的皮下（SC）给药疗法。该疗法已在 RYBREVANT（阿米万单抗-vmjw）的所有适应症中获得批准。</p>
<p>与传统的静脉（IV）给药相比，RYBREVANT FASPRO 在患者便利性和医疗效率方面提供了显著优势。给药时间从几个小时缩短至仅五分钟——远低于化疗方案，后者可能需要长达一个小时。</p>
<p>临床数据还显示了安全性结果的改善。皮下给药将给药相关反应（ARRs）减少了约五倍，SC 组的发生率为 13%，而 IV 组为 66%。此外，静脉血栓栓塞（VTE）的发生率也较低，SC 组为 11%，而 IV 组为 18%。</p>
<p>欲获取更多健康新闻，请访问 rttnews.com。</p>
<p>如有意见和反馈，请联系：editorial@rttnews.com</p>
<p>商业新闻</p>

强生

<p>美国食品药品监督管理局（FDA）已批准强生公司的 RYBREVANT FASPRO，这是首个用于 EGFR 突变非小细胞肺癌的皮下治疗方法。这种新的给药方式在患者便利性和医疗效率方面具有显著优势，将给药时间缩短至五分钟，并降低了与静脉给药相比的给药相关反应和静脉血栓栓塞的发生率</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>作为您在 Google 上的首选新闻来源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>Johnson &amp; Johnson (JNJ) announced that the U.S. Food and Drug Administration has approved RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj), the first and only subcutaneously (SC) administered therapy for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). The therapy is approved across all indications of RYBREVANT (amivantamab-vmjw).</p>
<div class="lb-trans"><p>强生（Johnson &amp; Johnson，JNJ）宣布，美国食品和药物管理局（FDA）已批准 RYBREVANT FASPRO（阿米万单抗和透明质酸酶-lpuj），这是首个也是唯一一个用于治疗表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC）患者的皮下（SC）给药疗法。该疗法已在 RYBREVANT（阿米万单抗-vmjw）的所有适应症中获得批准。</p>
</div><p>Compared to traditional intravenous (IV) delivery, RYBREVANT FASPRO offers significant advantages in patient convenience and healthcare efficiency. Administration time is reduced from several hours to just five minutes — far less than chemotherapy-based regimens, which can take up to an hour.</p>
<div class="lb-trans"><p>与传统的静脉（IV）给药相比，RYBREVANT FASPRO 在患者便利性和医疗效率方面提供了显著优势。给药时间从几个小时缩短至仅五分钟——远低于化疗方案，后者可能需要长达一个小时。</p>
</div><p>Clinical data also demonstrated improved safety outcomes. Subcutaneous delivery reduced administration-related reactions (ARRs) by approximately fivefold, with 13 percent incidence in the SC arm compared to 66 percent in the IV arm. Additionally, venous thromboembolism (VTE) incidence was lower, at 11 percent in the SC arm versus 18 percent in the IV arm.</p>
<div class="lb-trans"><p>临床数据还显示了安全性结果的改善。皮下给药将给药相关反应（ARRs）减少了约五倍，SC 组的发生率为 13%，而 IV 组为 66%。此外，静脉血栓栓塞（VTE）的发生率也较低，SC 组为 11%，而 IV 组为 18%。</p>
</div><p>For More Such Health News, visit rttnews.com.</p>
<div class="lb-trans"><p>欲获取更多健康新闻，请访问 rttnews.com。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意见和反馈，请联系：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商业新闻</p>
</div>

美国食品药品监督管理局（FDA）批准了强生公司的 RYBREVANT FASPRO，这是首个用于治疗 EGFR 突变型非小细胞肺癌的皮下注射疗法